



Revision date: 25-Jul-2016 Version: 1.0 Page 1 of 7

# 1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND THE COMPANY/UNDERTAKING

**Product Identifier** 

Material Name: Adenosine Injection, USP (Hospira Inc.)

Trade Name: Adenosine Injection, USP

Chemical Family: Not determined

Relevant Identified Uses of the Substance or Mixture and Uses Advised Against

Intended Use: Pharmaceutical product

Details of the Supplier of the Safety Data Sheet

Hospira, A Pfizer Company 275 North Field Drive Lake Forest, Illinois 60045

1-800-879-3477

Hospira UK Limited Horizon

Honey Lane Hurley

Maidenhead, SL6 6RJ

United Kingdom

Emergency telephone number:

International CHEMTREC (24 hours): +1-703-527-3887

Emergency telephone number: CHEMTREC (24 hours): 1-800-42

CHEMTREC (24 hours): 1-800-424-9300 Contact E-Mail: pfizer-MSDS@pfizer.com

# 2. HAZARDS IDENTIFICATION

**Classification of the Substance or Mixture** 

GHS - Classification Not classified as hazardous

**Label Elements** 

Signal Word: Not Classified

Hazard Statements: Not classified in accordance with international standards for workplace safety.

Other Hazards No data available

**Note:** This document has been prepared in accordance with standards for workplace safety, which

requires the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warning included may not apply in all cases.

Your needs may vary depending upon the potential for exposure in your workplace.

# 3. COMPOSITION / INFORMATION ON INGREDIENTS

Ingredient	CAS Number	EU EINECS/ELINCS List	GHS Classification	%
Adenosine	58-61-7	200-389-9	Not Listed	0.3

Material Name: Adenosine Injection, USP (Hospira Inc.)

Page 2 of 7

Revision date: 25-Jul-2016 Version: 1.0

3. COMPOSITION / INFORMATION ON INGREDIENTS						
Water for Injection	7732-18-5	231-791-2	Not Listed	*		
SODIUM CHLORIDE	7647-14-5	231-598-3	Not Listed	*		

Additional Information: \* Proprietary

Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety. In accordance with 29 CFR 1910.1200, the exact percentage composition of this

mixture has been withheld as a trade secret.

# 4. FIRST AID MEASURES

**Description of First Aid Measures** 

Eye Contact: Flush eye(s) immediately with plenty of water. If irritation occurs or persists, get medical

attention.

**Skin Contact:** Rinse with plenty of water If skin irritation persists, call a physician.

**Ingestion:** Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not

induce vomiting unless directed by medical personnel. Seek medical attention immediately.

**Inhalation:** Move to fresh air. If discomfort occurs, get medical attention.

Most Important Symptoms and Effects, Both Acute and Delayed

**Symptoms and Effects of** For information on potential signs and symptoms of exposure, See Section 2 - Hazards

**Exposure:** Identification and/or Section 11 - Toxicological Information.

Medical Conditions None known

Aggravated by Exposure:

Indication of the Immediate Medical Attention and Special Treatment Needed

Notes to Physician: None

# 5. FIRE FIGHTING MEASURES

**Extinguishing Media:** As for primary cause of fire.

Special Hazards Arising from the Substance or Mixture

**Hazardous Combustion** Formation of toxic gases is possible during heating or fire.

**Products:** 

**Fine / Explosion Hazards:** Fine particles (such as dust and mists) may fuel fires/explosions.

Advice for Fire-Fighters

During all fire fighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

### 6. ACCIDENTAL RELEASE MEASURES

### Personal Precautions, Protective Equipment and Emergency Procedures

Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

#### **Environmental Precautions**

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

### Methods and Material for Containment and Cleaning Up

Measures for Cleaning / Contain the source of spill if it is safe to do so. Collect spill with absorbent material. Clean spill

Collecting: area thoroughly.

Material Name: Adenosine Injection, USP (Hospira Inc.)

Page 3 of 7

Revision date: 25-Jul-2016 Version: 1.0

Additional Consideration for Large Spills:

Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

### 7. HANDLING AND STORAGE

### **Precautions for Safe Handling**

Avoid breathing vapor or mist. Avoid contact with eyes, skin and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

### Conditions for Safe Storage, Including any Incompatibilities

Storage Conditions: Store as directed by product packaging. Do not refrigerate.

Storage Temperature: 20-25deg C Incompatible Materials: None known

Specific end use(s): Pharmaceutical drug product

### 8. EXPOSURE CONTROLS / PERSONAL PROTECTION

#### **Control Parameters**

Refer to available public information for specific member state Occupational Exposure Limits.

#### **SODIUM CHLORIDE**

Latvia OEL - TWA 5 mg/m³
Lithuania OEL - TWA 5 mg/m³

The purpose of the Occupational Exposure Band (OEB) classification system is to separate substances into different Hazard categories when the available data are sufficient to do so, but inadequate to establish an Occupational Exposure Limit (OEL). The OEB given is based upon an analysis of all currently available data; as such, this value may be subject to revision when new information becomes available.

### Adenosine

Pfizer Occupational Exposure OEB 3 (control exposure to the range of 10ug/m³ to < 100ug/m³)

Band (OEB):

**Exposure Controls** 

**Engineering Controls:** Engineering controls should be used as the primary means to control exposures. General

room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne

contamination levels below the exposure limits listed above in this section.

Personal Protective

Equipment:

Refer to applicable national standards and regulations in the selection and use of personal

protective equipment (PPE).

**Hands:** Impervious gloves (e.g. Nitrile, etc.) are recommended if skin contact with drug product is

possible and for bulk processing operations. (Protective gloves must meet the standards in

accordance with EN374, ASTM F1001 or international equivalent.)

Eyes: Wear safety glasses as minimum protection. (Safety glasses must meet the standards in

accordance with EN166, ANSI Z87.1 or international equivalent.)

**Skin:** Impervious protective clothing is recommended if skin contact with drug product is possible and

for bulk processing operations. (Protective clothing must meet the standards in accordance

with EN13982, ANSI 103 or international equivalent.)

Respiratory protection: Under normal conditions of use, if the applicable Occupational Exposure Limit (OEL) is

exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL (e.g. particulate respirator with a half mask, P3 filter). (Respirators must meet the standards in accordance with EN140, EN143, ASTM F2704-10 or international

equivalent.)

**Molecular Weight:** 

Mixture

Material Name: Adenosine Injection, USP (Hospira Inc.)

Revision date: 25-Jul-2016

Page 4 of 7

Version: 1.0

Nevision date: 23-3di-2010 Version: 1

# 9. PHYSICAL AND CHEMICAL PROPERTIES

Physical State:LiquidColor:ColourlessOdor:No data available.Odor Threshold:No data available.

Molecular Formula: Mixture

Solvent Solubility: No data available

Water Solubility: Soluble pH: Soluble 4.5-7.5

Melting/Freezing Point (°C):

Boiling Point (°C):

No data available.

No data available.

Partition Coefficient: (Method, pH, Endpoint, Value)

Adenosine
No data available
Water for Injection
No data available
SODIUM CHLORIDE
No data available

**Decomposition Temperature (°C):** No data available.

Evaporation Rate (Gram/s):

Vapor Pressure (kPa):

Vapor Density (g/ml):

Relative Density:

No data available

Flammablity:

Autoignition Temperature (Solid) (°C):

Flammability (Solids):

Flash Point (Liquid) (°C):

Upper Explosive Limits (Liquid) (% by Vol.):

Lower Explosive Limits (Liquid) (% by Vol.):

No data available

No data available

No data available

# 10. STABILITY AND REACTIVITY

Reactivity: No data available

Chemical Stability: Stable under normal conditions of use.

**Possibility of Hazardous Reactions** 

Oxidizing Properties: None

**Conditions to Avoid:** Fine particles (such as dust and mists) may fuel fires/explosions.

Incompatible Materials: None known Hazardous Decomposition None known

Products:

# 11. TOXICOLOGICAL INFORMATION

Information on Toxicological Effects

General Information: The information included in this section describes the potential hazards of the individual

ingredients.

**Known Clinical Effects:** Adverse effects associated with therapeutic use include facial flushing, shortness of breath

(dyspnea), headache, lightheadedness, dizziness, tingling/itching (paresthesia), decrease in

blood pressure (hypotension), nervousness, irregular heartbeat (cardiac arrhythmia).

Material Name: Adenosine Injection, USP (Hospira Inc.)

Revision date: 25-Jul-2016

Page 5 of 7

Version: 1.0

Version and the second second

# 11. TOXICOLOGICAL INFORMATION

**Acute Toxicity: (Species, Route, End Point, Dose)** 

Adenosine

Mouse Oral LD50 > 20,000 mg/kg

**SODIUM CHLORIDE** 

Rat Sub-tenon injection (eye) LC50/1hr > 42 g/m<sup>3</sup>

Rat Oral LD 50 3g/kg Mouse Oral LD 50 4g/kg Rabbit Dermal LD 50 > 10g/kg

Irritation / Sensitization: (Study Type, Species, Severity)

Adenosine

Skin Irritation Negative

Eye Irritation (In Vitro, HET-CAM) Mild

**SODIUM CHLORIDE** 

Skin Irritation Rabbit Mild Eye Irritation Rabbit Mild

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Adenosine

Bacterial Mutagenicity (Ames) Bacteria Negative

Carcinogen Status: None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

# 12. ECOLOGICAL INFORMATION

**Environmental Overview:** Environmental properties have not been investigated. Releases to the environment should be

avoided.

Toxicity: No data available

Persistence and Degradability: No data available

Bio-accumulative Potential: No data available

Mobility in Soil: No data available

Material Name: Adenosine Injection, USP (Hospira Inc.)

Revision date: 25-Jul-2016

Page 6 of 7

Version: 1.0

TOURS TO THE POLICE TO THE POL

# 13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods: Dispose of waste in accordance with all applicable laws and regulations. Member State

specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental

releases. This may include destructive techniques for waste and wastewater.

### 14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

# 15. REGULATORY INFORMATION

Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture

### Adenosine

CERCLA/SARA 313 Emission reporting

California Proposition 65

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

Standard for the Uniform Scheduling

Schedule 4

for Drugs and Poisons:

EU EINECS/ELINCS List 200-389-9

# Water for Injection

CERCLA/SARA 313 Emission reporting

California Proposition 65

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

REACH - Annex IV - Exemptions from the

Not Listed
Present
Present

obligations of Register:

EU EINECS/ELINCS List 231-791-2

### **SODIUM CHLORIDE**

CERCLA/SARA 313 Emission reporting

California Proposition 65

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

Present

EU EINECS/ELINCS List

Not Listed

Present

231-598-3

Material Name: Adenosine Injection, USP (Hospira Inc.)

Revision date: 25-Jul-2016

Page 7 of 7

Version: 1.0

TOISION date. 20 day 2010

# **16. OTHER INFORMATION**

**Data Sources:** Pfizer proprietary drug development information. Publicly available toxicity information.

Revision date: 25-Jul-2016

Product Stewardship Hazard Communication

Prepared by: Pfizer Global Environment, Health, and Safety Operations

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

**End of Safety Data Sheet**